DSM Receives Profiles in Sustainability Award for Pharmaceutical Manufacturing Technology
PARSIPPANY, N.J., Feb. 18 /PRNewswire/ -- DSM Pharmaceutical Products, based in Parsippany, NJ, today announced that it has received a Profiles in Sustainability award from United Business Media and ICIS Chemical Business. United Business Media Limited is a leading global business media company and parent of InformexUSA, where the award was announced today in San Francisco. Organized by UBM International Media, Informex, taking place February 16-19, 2010, at San Francisco's Moscone Center South, is the leading meeting place for buyers and sellers of high-value chemistry for a broad range of applications.
DSM was considered based on its process intensification activities, such as micro reactor technology, and their "green chemistry toolbox" for the sustainable, cost-effective production of active pharmaceutical ingredients. "This represents our commitment to understanding our customers' needs and the need for viable manufacturing solutions in the future." stated Bob Hartmayer , President and CEO of DSM Pharmaceutical Products. As part of DSM's global commitment to sustainability, for six years DSM has ranked at the top of the Dow Jones Sustainability Index due to its continuous drive to embed sustainability metrics into process design and manufacturing, and to provide transparency about this in the annual Triple P (People, Planet, Profit) report.
"The Profiles in Sustainability award was born from a need to recognize that sustainable chemistry was not just a passing fad or a niche branch for the chemical industry. Informex is leading the way in bringing green chemistry to the forefront in traditional chemical forums. We were overwhelmed at the outpouring of interest in the award, and the quality of the papers. The real factor that made our winners stand-out was their current viability in the market." stated Jennifer Jessup , Brand Director of Informex.
A panel of industry experts coordinated by ICIS selected five submitting companies to be recognized. "DSM is proud of its broad technological toolbox in chemistry, biology, and process technology and material sciences, which strongly contribute to our leadership position in sustainable manufacturing. Also, optimizing first generation processes by driving down the cost curve is crucial for the commercial success of pharmaceutical compounds," commented Luca Mantovani , President and Business Unit Director of DSM Pharma Chemicals. DSM's green chemistry tool box is increasingly used to bring down these manufacturing costs and at the same time "green-up" the process. The DSM tool box involves chemo- and biocatalysis, process intensification, and the proactive management of learning curves to increase yield and reduce waste.
DSM also exhibited as part of Informex Pharma and at the Green Chemistry Pavilion as well as speaking at the Green Chemistry Breakfast Briefing developed in partnership with the American Chemical Society's Green Chemistry Institute®, of which DSM is an associate member of the Pharmaceutical Roundtable.
DSM Pharmaceutical Products
DSM Pharmaceutical Products is a global provider of high quality custom contract manufacturing and development services to the pharmaceutical and biopharmaceutical industries. DSM contract manufacturing services include: chemical development, registered intermediates, registered starting materials, active pharmaceutical ingredients (API's), mammalian cell production of monoclonal antibodies and proteins, formulation development, clinical trial manufacturing and finished dose form manufacturing of solids, semi-solids, and scheduled drugs, aseptic liquid and lyophilized products. More information: www.dsmpharmaceuticals.com
DSM – the Life Sciences and Materials Sciences Company
Royal DSM N.V. creates innovative products and services in Life Sciences and Materials Sciences that contribute to the quality of life. DSM's products and services are used globally in a wide range of markets and applications, supporting a healthier, more sustainable and more enjoyable way of life. End markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrical and electronics, life protection and housing. DSM has annual net sales of EUR 9.3 billion and employs some 23,500 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information: www.dsm.com
For more information:
This press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law.
SOURCE DSM Pharmaceutical Products
More by this Source
DSM and DecImmune Therapeutics Sign Agreement to Develop N2 Pathway Blocking Antibody
Apr 22, 2013, 02:00 ET
DSM signs Master Supply Agreement with Eisai Inc.
Mar 05, 2013, 02:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.